Cargando…
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer hi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102840/ https://www.ncbi.nlm.nih.gov/pubmed/36662819 http://dx.doi.org/10.1158/1078-0432.CCR-22-3334 |
_version_ | 1785025771596677120 |
---|---|
author | Meric-Bernstam, Funda Ford, James M. O'Dwyer, Peter J. Shapiro, Geoffrey I. McShane, Lisa M. Freidlin, Boris O'Cearbhaill, Roisin E. George, Suzanne Glade-Bender, Julia Lyman, Gary H. Tricoli, James V. Patton, David Hamilton, Stanley R. Gray, Robert J. Hawkins, Douglas S. Ramineni, Bhanumati Flaherty, Keith T. Grivas, Petros Yap, Timothy A. Berlin, Jordan Doroshow, James H. Harris, Lyndsay N. Moscow, Jeffrey A. |
author_facet | Meric-Bernstam, Funda Ford, James M. O'Dwyer, Peter J. Shapiro, Geoffrey I. McShane, Lisa M. Freidlin, Boris O'Cearbhaill, Roisin E. George, Suzanne Glade-Bender, Julia Lyman, Gary H. Tricoli, James V. Patton, David Hamilton, Stanley R. Gray, Robert J. Hawkins, Douglas S. Ramineni, Bhanumati Flaherty, Keith T. Grivas, Petros Yap, Timothy A. Berlin, Jordan Doroshow, James H. Harris, Lyndsay N. Moscow, Jeffrey A. |
author_sort | Meric-Bernstam, Funda |
collection | PubMed |
description | Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer histology. Although many therapies are now approved for the treatment of cancers harboring specific genomic alterations, most patients do not respond to therapies targeting a single alteration. Further, when antitumor responses do occur, they are often not durable due to the development of drug resistance. Therefore, there is a great need to identify rational combination therapies that may be more effective. To address this need, the NCI and National Clinical Trials Network have developed NCI-ComboMATCH, the successor to NCI-MATCH. Like the original trial, NCI-ComboMATCH is a signal-seeking study. The goal of ComboMATCH is to overcome drug resistance to single-agent therapy and/or utilize novel synergies to increase efficacy by developing genomically-directed combination therapies, supported by strong preclinical in vivo evidence. Although NCI-MATCH was mainly comprised of multiple single-arm studies, NCI-ComboMATCH tests combination therapy, evaluating both combination of targeted agents as well as combinations of targeted therapy with chemotherapy. Although NCI-MATCH was histology agnostic with selected tumor exclusions, ComboMATCH has histology-specific and histology-agnostic arms. Although NCI-MATCH consisted of single-arm studies, ComboMATCH utilizes single-arm as well as randomized designs. NCI-MATCH had a separate, parallel Pediatric MATCH trial, whereas ComboMATCH will include children within the same trial. We present rationale, scientific principles, study design, and logistics supporting the ComboMATCH study. |
format | Online Article Text |
id | pubmed-10102840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-101028402023-04-15 National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) Meric-Bernstam, Funda Ford, James M. O'Dwyer, Peter J. Shapiro, Geoffrey I. McShane, Lisa M. Freidlin, Boris O'Cearbhaill, Roisin E. George, Suzanne Glade-Bender, Julia Lyman, Gary H. Tricoli, James V. Patton, David Hamilton, Stanley R. Gray, Robert J. Hawkins, Douglas S. Ramineni, Bhanumati Flaherty, Keith T. Grivas, Petros Yap, Timothy A. Berlin, Jordan Doroshow, James H. Harris, Lyndsay N. Moscow, Jeffrey A. Clin Cancer Res Perspectives Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alterations is effective, irrespective of the cancer histology. Although many therapies are now approved for the treatment of cancers harboring specific genomic alterations, most patients do not respond to therapies targeting a single alteration. Further, when antitumor responses do occur, they are often not durable due to the development of drug resistance. Therefore, there is a great need to identify rational combination therapies that may be more effective. To address this need, the NCI and National Clinical Trials Network have developed NCI-ComboMATCH, the successor to NCI-MATCH. Like the original trial, NCI-ComboMATCH is a signal-seeking study. The goal of ComboMATCH is to overcome drug resistance to single-agent therapy and/or utilize novel synergies to increase efficacy by developing genomically-directed combination therapies, supported by strong preclinical in vivo evidence. Although NCI-MATCH was mainly comprised of multiple single-arm studies, NCI-ComboMATCH tests combination therapy, evaluating both combination of targeted agents as well as combinations of targeted therapy with chemotherapy. Although NCI-MATCH was histology agnostic with selected tumor exclusions, ComboMATCH has histology-specific and histology-agnostic arms. Although NCI-MATCH consisted of single-arm studies, ComboMATCH utilizes single-arm as well as randomized designs. NCI-MATCH had a separate, parallel Pediatric MATCH trial, whereas ComboMATCH will include children within the same trial. We present rationale, scientific principles, study design, and logistics supporting the ComboMATCH study. American Association for Cancer Research 2023-04-14 2023-01-20 /pmc/articles/PMC10102840/ /pubmed/36662819 http://dx.doi.org/10.1158/1078-0432.CCR-22-3334 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Perspectives Meric-Bernstam, Funda Ford, James M. O'Dwyer, Peter J. Shapiro, Geoffrey I. McShane, Lisa M. Freidlin, Boris O'Cearbhaill, Roisin E. George, Suzanne Glade-Bender, Julia Lyman, Gary H. Tricoli, James V. Patton, David Hamilton, Stanley R. Gray, Robert J. Hawkins, Douglas S. Ramineni, Bhanumati Flaherty, Keith T. Grivas, Petros Yap, Timothy A. Berlin, Jordan Doroshow, James H. Harris, Lyndsay N. Moscow, Jeffrey A. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) |
title | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) |
title_full | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) |
title_fullStr | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) |
title_full_unstemmed | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) |
title_short | National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) |
title_sort | national cancer institute combination therapy platform trial with molecular analysis for therapy choice (combomatch) |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102840/ https://www.ncbi.nlm.nih.gov/pubmed/36662819 http://dx.doi.org/10.1158/1078-0432.CCR-22-3334 |
work_keys_str_mv | AT mericbernstamfunda nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT fordjamesm nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT odwyerpeterj nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT shapirogeoffreyi nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT mcshanelisam nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT freidlinboris nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT ocearbhaillroisine nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT georgesuzanne nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT gladebenderjulia nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT lymangaryh nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT tricolijamesv nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT pattondavid nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT hamiltonstanleyr nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT grayrobertj nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT hawkinsdouglass nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT raminenibhanumati nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT flahertykeitht nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT grivaspetros nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT yaptimothya nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT berlinjordan nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT doroshowjamesh nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT harrislyndsayn nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch AT moscowjeffreya nationalcancerinstitutecombinationtherapyplatformtrialwithmolecularanalysisfortherapychoicecombomatch |